Skip to main content
Eupraxia Pharmaceuticals Inc. (EPRX)
NASDAQ: EPRX · Real-Time Price · USD
2.990
+0.040 (1.36%)
Dec 20, 2024, 4:00 PM EST - Market closed

Eupraxia Pharmaceuticals Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for EPRX stock has a target of 9.00, which predicts an increase of 201.00% from the current stock price of 2.99.

Analyst Consensus: Strong Buy
Target Low Average Median High
Price $9.00 $9.00 $9.00 $9.00
Change +201.00% +201.00% +201.00% +201.00%
* Price targets were last updated on Nov 14, 2024.

Analyst Ratings

According to 1 stock analyst, the rating for EPRX is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating Dec '24
Strong Buy 1
Buy 0
Hold 0
Sell 0
Strong Sell 0
Total 1

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
Brandon Folkes
Rodman & Renshaw
 Rodman & Renshaw
Strong Buy
Initiates
$9
 Strong Buy Initiates $9 +201.00% Nov 14, 2024
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.61
from -1.17
EPS Next Year
-0.69
from -0.61
Fiscal Year FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026
Period Ending Dec 31, 2019 Dec 31, 2020 Dec 31, 2021 Dec 31, 2022 Dec 31, 2023 Dec 31, 2024 Dec 31, 2025 Dec 31, 2026
Revenue
-------46.31M
Revenue Growth
--------
EPS
-1.17-0.65-1.93-0.96-1.17-0.61-0.69-
EPS Growth
--------
Forward PE
--------
No. Analysts -----333
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 202420252026202720282029
High n/a n/a 47.7M
Avg n/a n/a 46.3M
Low n/a n/a 44.5M

Revenue Growth

Revenue Growth 202420252026202720282029
High - - -
Avg - - -
Low - - -

EPS Forecast

EPS 202420252026202720282029
High -0.63 -0.71 -
Avg -0.61 -0.69 -
Low -0.58 -0.67 -

EPS Growth

EPS Growth 202420252026202720282029
High - - -
Avg - - -
Low - - -
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.